Article

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer.

2022-06-01

Abstract excerpt

Poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged as the most promising targeted therapeutic intervention for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). However, the clinical utility of PARPi has been limited to a subset of patients who harbor aberrations in the homologous recombination (HR) pathway. Here, we report that targeting MALAT1, an oncogenic lncRNA, known to be elev...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 45487d11-ce4d-5685-be64-662e73690e1f
DOI: 10.1101/2022.06.01.494272

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer.DOI 10.1101/2022.06.01.494272Read

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate CancerSemantic proximity Read

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate CancerSemantic proximity Read

PARP inhibitors for homologous recombination-deficient prostate cancer.Semantic proximity Read

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read

Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolutionSemantic proximity Read

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2Semantic proximity Read

Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancerSemantic proximity Read

The molecular underpinnings of prostate cancer: impacts on management and pathology practiceSemantic proximity Read

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity Read

A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancerSemantic proximity Read